Author

Tim W. Failes

Australian Cancer Research FoundationORCID 0000-0003-4618-1057Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Greg M. ArndtiD· 2 shared Alexandra BomaneiD· 1 shared Alvaro A. MartineziD· 1 shared Alvin KamiliiD· 1 shared Andrew J. GiffordiD· 1 shared Angela LiniD· 1 shared Baptiste MouyssetiD· 1 shared Brandon A. HearniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Greg M. ArndtORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 10, 2026

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma

Alvin Kamili, Brandon A. Hearn, Isabella Temelkoska…·Jamie I. Fletcher

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

DOI 10.64898/2026.09.06.749004

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 9, 2026

Reverse molecular pharmacology identifies the non-canonical axis of IRAK as a chemoresistance factor in neuroblastoma

Marion Le Grand, Chen Buxbaum, Mathilde Kerhervé…·Eddy Pasquier

This study identifies IRAK1 as a chemoresistance factor in neuroblastoma and shows synergy between IRAK1 inhibition and various drugs in preclinical models.

DOI 10.64898/2026.01.09.697473

humanbulk RNA-seq

𝕏 PostBluesky